We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 373

Canada moves closer to joining the Hague Agreement with the release of proposed new Industrial Design Regulations
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • December 12 2017

On December 9, 2017 Canada’s Governor-in-Council took the formal step of publishing proposed new Industrial Design Regulations (the proposed


Streamlined Canadian trademark litigation Court of Appeal opens door to full compensation
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • December 11 2017

A recent decision of the Federal Court of Appeal sheds light on a streamlined litigation procedure that brand owners may find attractive. In Group III


Six Key Trademark Filing and Protection Strategies for Canada in 2018
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • December 6 2017

As 2017 draws to a close and we begin to look forward to the new year, the countdown to the implementation of Canada’s new trademark law begins in


Canada releases proposed amendments to Regulations governing patented medicines pricing
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • December 4 2017

On December 2, 2017 Canada’s Governor-in-Council published proposed Regulations Amending the Patented Medicines Regulations (“the proposed


Federal Court declines to assess litigation funding arrangement
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • December 1 2017

Seedling Life Science Ventures (“Seedlings”) is the plaintiff in a patent infringement action against Pfizer relating to Patent No. 2,486,935 and auto


Canada’s new linkage litigation scheme: a comparison to Hatch-Waxman
  • Smart & Biggar/Fetherstonhaugh
  • USA, Canada
  • December 1 2017

The September 21, 2017 amendments to the Patented Medicines (Notice of Compliance) Regulations introduced a new scheme


Health Canada publishes final guidance documents on quality requirements for regulatory filings
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • November 30 2017

On October 30, 2017, Health Canada published the final version of the following guidance documents and template: Guidance Document:


Federal Court finds PMPRB unreasonable in finding Galderma patent 'pertains to' medicine in DIFFERIN
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • November 30 2017

In a November 9, 2017 decision, Justice Phelan of the Federal Court found that the Patented Medicine Prices Review Board Panel (Board) was


Pfizer obtains orders of prohibition on polymorphic form patent
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • October 20 2017

On September 22, the Federal Court, in a pair of decisions, granted Orders of prohibition under the Patented Medicines (Notice of Compliance


Update on AstraZeneca SCC and developments on “overpromising” under grounds other than utility
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • October 20 2017

On October 23, 2017, the Supreme Court of Canada dismissed Apotex’s motion to amend the Supreme Court of Canada’s judgment in AstraZeneca Canada Inc v